Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Mismatch Repair a Potential Biomarker for PD-1 Inhibition

May 29th 2015

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

Proteoglycan Assay Shows Potential as Adjunct to PSA Measurement

May 18th 2015

A cell-surface proteoglycan found on prostate cancer cells but not normal prostate tissue demonstrated good specificity as a blood test for prostate cancer.

Bone Metastases in CRPC: Prognostic for Survival

May 17th 2015

Biomarkers Indicative of Bone Lesions in Prostate Cancer

May 17th 2015

Asymptomatic Versus Symptomatic Bone Metastases in Prostate Cancer

May 17th 2015

Symptomatic Bone Lesions in CRPC: More Options for Treatment

May 17th 2015

Reducing Skeletal-Related Events in Prostate Cancer

May 17th 2015

Administering Radium-223 for mCRPC

May 17th 2015

Reassessing Trial Endpoints for CRPC

May 17th 2015

AUA2015: Biomarkers, Enzalutamide, and ARN509

May 17th 2015

Combining and Sequencing Sipuleucel-T in CRPC

May 17th 2015

Siteman Cancer Center Houses Broad Research Program

May 15th 2015

Venetoclax Breakthrough Designation, Zarxio Legal Update, and More

May 15th 2015

Taking Lung Cancer Care into the Precision Medicine Era

May 5th 2015

The recent approval of nivolumab in the nonâ€“small cell lung cancer setting marks a unique shift in the treatment landscape of this malignancy, one that harnesses the patient's own immune system to target the tumors. However, there are challenges in using these agents.

Dr. Alan Miller on Benefits of Liquid Biopsy

April 29th 2015

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System discusses the benefits of liquid biopsy.

The Precision Medicine Misconception

April 28th 2015

Amid the increasingly public discussion and often vigorous debate surrounding the general topic of precision cancer medicine, there appears to be a misconception of what the term is meant to imply.

Improving Treatment Requires Collaboration and Transparency

April 26th 2015

Application of Payment Reform Models in Oncology

April 26th 2015

Practical Application and Utility of EMRs

April 26th 2015

Coverage Decisions for Off-Label Treatments

April 26th 2015